Eliem Therapeutics Stock Buy Hold or Sell Recommendation
| ELYM Stock | USD 3.75 0.12 3.10% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Eliem Therapeutics is 'Hold'. Macroaxis provides Eliem Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ELYM positions. The advice algorithm takes into account all of Eliem Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Eliem Therapeutics' buy or sell advice are summarized below:
Real Value 3.84 | Target Price 4.5 | Hype Value 3.95 | Market Value 3.75 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Eliem Therapeutics given historical horizon and risk tolerance towards Eliem Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Eliem Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Eliem |
Execute Eliem Therapeutics Buy or Sell Advice
The Eliem recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Eliem Therapeutics. Macroaxis does not own or have any residual interests in Eliem Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eliem Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Modest | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Eliem Therapeutics Trading Alerts and Improvement Suggestions
| Eliem Therapeutics is way too risky over 90 days horizon | |
| Eliem Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (35.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eliem Therapeutics currently holds about 122.95 M in cash with (20.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eliem Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN |
Eliem Therapeutics Returns Distribution Density
The distribution of Eliem Therapeutics' historical returns is an attempt to chart the uncertainty of Eliem Therapeutics' future price movements. The chart of the probability distribution of Eliem Therapeutics daily returns describes the distribution of returns around its average expected value. We use Eliem Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eliem Therapeutics returns is essential to provide solid investment advice for Eliem Therapeutics.
| Mean Return | 0.73 | Value At Risk | -6.23 | Potential Upside | 4.17 | Standard Deviation | 9.52 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eliem Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Eliem Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eliem Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eliem Therapeutics backward and forwards among themselves. Eliem Therapeutics' institutional investor refers to the entity that pools money to purchase Eliem Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2023-12-31 | 18.4 K | Hpm Partners Llc | 2023-12-31 | 13.8 K | Chicago Partners Investment Group Llc | 2023-12-31 | 12.2 K | Renaissance Technologies Corp | 2023-12-31 | 10.6 K | Advisor Group Holdings, Inc. | 2023-12-31 | 8.3 K | Tower Research Capital Llc | 2023-12-31 | 3.5 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.7 K | Qube Research & Technologies | 2023-12-31 | 981 | Wells Fargo & Co | 2023-12-31 | 48.0 | Ra Capital Management, Llc | 2023-12-31 | 13.2 M | Bml Capital Management Llc | 2023-12-31 | 2.2 M |
Eliem Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Eliem Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Eliem Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Eliem stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.79 | |
β | Beta against NYSE Composite | -0.92 | |
σ | Overall volatility | 9.73 | |
Ir | Information ratio | 0.07 |
Eliem Therapeutics Volatility Alert
Eliem Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eliem Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eliem Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Eliem Therapeutics Fundamentals Vs Peers
Comparing Eliem Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Eliem Therapeutics' direct or indirect competition across all of the common fundamentals between Eliem Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Eliem Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Eliem Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Eliem Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Eliem Therapeutics to competition |
| Fundamentals | Eliem Therapeutics | Peer Average |
| Return On Equity | -0.3 | -0.31 |
| Return On Asset | -0.11 | -0.14 |
| Current Valuation | 825.11 K | 16.62 B |
| Shares Outstanding | 27.72 M | 571.82 M |
| Shares Owned By Insiders | 26.12 % | 10.09 % |
| Shares Owned By Institutions | 67.24 % | 39.21 % |
| Number Of Shares Shorted | 13.22 K | 4.71 M |
| Price To Book | 1.00 X | 9.51 X |
| EBITDA | (40.27 M) | 3.9 B |
| Net Income | (35.12 M) | 570.98 M |
| Cash And Equivalents | 122.95 M | 2.7 B |
| Cash Per Share | 4.63 X | 5.01 X |
| Total Debt | 349 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 17.48 X | 2.16 X |
| Book Value Per Share | 3.88 X | 1.93 K |
| Cash Flow From Operations | (20.6 M) | 971.22 M |
| Short Ratio | 1.81 X | 4.00 X |
| Earnings Per Share | (1.30) X | 3.12 X |
| Target Price | 4.5 | |
| Number Of Employees | 9 | 18.84 K |
| Beta | 0.51 | -0.15 |
| Market Capitalization | 107.27 M | 19.03 B |
| Total Asset | 110.47 M | 29.47 B |
| Retained Earnings | (155.98 M) | 9.33 B |
| Working Capital | 107.42 M | 1.48 B |
| Net Asset | 110.47 M |
Note: Disposition of tradable shares by Ratcliffe Liam of Eliem Therapeutics subject to Rule 16b-3 [view details]
Eliem Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eliem . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Eliem Therapeutics Buy or Sell Advice
When is the right time to buy or sell Eliem Therapeutics? Buying financial instruments such as Eliem Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 4.6M | 5.0M | 2.5M | 3.1M | Total Assets | 173.2M | 135.0M | 110.5M | 102.2M |
Use Investing Ideas to Build Portfolios
In addition to having Eliem Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Financials Thematic Idea Now
Financials
Companies that provide financial services to business or retail customers. The Financials theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Eliem Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Eliem Stock, please use our How to Invest in Eliem Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Eliem Stock analysis
When running Eliem Therapeutics' price analysis, check to measure Eliem Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eliem Therapeutics is operating at the current time. Most of Eliem Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eliem Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eliem Therapeutics' price. Additionally, you may evaluate how the addition of Eliem Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Eliem Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eliem Therapeutics. If investors know Eliem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eliem Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.30) | Return On Assets (0.11) | Return On Equity (0.30) |
The market value of Eliem Therapeutics is measured differently than its book value, which is the value of Eliem that is recorded on the company's balance sheet. Investors also form their own opinion of Eliem Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eliem Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eliem Therapeutics' market value can be influenced by many factors that don't directly affect Eliem Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eliem Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eliem Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eliem Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.